schizophrenia

Study Suggests A Simple Method for Regulating Depression, ADHD, and Other Disorders

By John Michael

A new study proposes an easy and inexpensive way to regulate conditions like depression, ADHD, bipolar disorder, and even schizophrenia. In the study’s abstract, Dr. Rhonda P. Patrick and Dr. Bruce N. Ames note that at least seventy percent of Americans suffer from a lack of this readily available treatment.

Their simple solution?

Get more sunshine. Eat more fish.

 In their study, Vitamin D and the Omega 3 Fatty Acids Control Serotonin Synthesis and Action, the doctors link the neurotransmitter serotonin to the regulation of executive function in the brain. Then they suggest that vitamin D and the two marine omega-3 fatty acids (EPA and DHA) encourage our brains to produce serotonin, thereby improving executive function in most people.

We propose a model whereby insufficient levels of vitamin D, EPA, or DHA, in combination with genetic factors and at key periods during development, would lead to dysfunctional serotonin activation and function and may be one underlying mechanism that contributes to neuropsychiatric disorders and depression.

The doctors conclude that increasing the intake of vitamin D, EPA, and DHA can enhance serotonin synthesis and reduce the severity of conditions in which poor executive function is characteristic, like ADHD, bipolar disorder, depression, and schizophrenia.

Whether or not you’re affected by these disorders, the fact that two-thirds of Americans suffer from a lack of vitamin D and omega-3 fatty acids suggests we might all benefit from taking this study’s advice. EPA and DHA are generally found in fish like salmon, sardines, cod, roe, mackerel and herring. Vitamin D is best obtained from sunlight.

So get outside and enjoy the sun! And if you live by the beach, take a fishing pole with you.

Abstract: Non Celiac Gluten sensitivity (NCGS)

"Non Celiac Gluten sensitivity (NCGS) was originally described in the 1980s and recently a “re-discovered” disorder characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected with either celiac disease (CD) or wheat allergy (WA). Although NCGS frequency is still unclear, epidemiological data have been generated that can help establishing the magnitude of the problem. Clinical studies further defined the identity of NCGS and its implications in human disease. An overlap between the irritable bowel syndrome (IBS) and NCGS has been detected, requiring even more stringent diagnostic criteria. Several studies suggested a relationship between NCGS and neuropsychiatric disorders, particularly autism and schizophrenia. The first case reports of NCGS in children have been described. Lack of biomarkers is still a major limitation of clinical studies, making it difficult to differentiate NCGS from other gluten related disorders. Recent studies raised the possibility that, beside gluten, wheat amylase-trypsin inhibitors and low-fermentable, poorly-absorbed, short-chain carbohydrates can contribute to symptoms (at least those related to IBS) experienced by NCGS patients. In this paper we report the major advances and current trends on NCGS."(bold added)

Reference: Non-Celiac Gluten Sensitivity: The New Frontier of Gluten Related Disorders